Aggregation of cardiovascular risk factors in a cohort of 40-year-olds participating in a population-based health screening program in Sweden DOI Creative Commons
Beata Borgström Bolmsjö, Emelie Stenman,

Anton Grundberg

и другие.

Archives of Public Health, Год журнала: 2024, Номер 82(1)

Опубликована: Ноя. 28, 2024

Abstract Background It is important to identify and evaluate cardiovascular risk factors at an early stage address them accordingly. Among the younger population, metabolic syndrome less common than in older ages. However, each separate factor still has additive effect on burden. Non-metabolic that occur population include family history, smoking, psychological distress socioeconomic vulnerability. In 2021 a voluntary health intervention program was introduced urban area Sweden where cohort of 40-year-olds invited for identification. The aim this study how tend aggregate individuals participating screening associate with non-metabolic factors. Methods This cross-sectional 1831 participants. Data from questionnaires baseline measurements were used calculate prevalence metabolic- (blood pressure, lipids, fasting plasma glucose, BMI, waist-hip ratio) (family history CVD, distress, vulnerability) CVD. SCORE2 calculated according algorithm provided by working group ESC (European Society Cardiology) Cardiovascular Risk Collaboration. Associations among estimated using logistic regression presented as odds ratios (ORs) 95% confidence intervals (CIs). Results More half had least one factor, more 1/3 considered be suffering distress. Furthermore, obesity or central demonstrated individual associations all study; smoking (1.49; 1.32–2.63), CVD (1.41; 1.14–1.73), vulnerability (1.60; 1.24–2.07), (1.40; 1.14–1.72). According 25% men moderate (2.5–7.5%) developing event within 5–10 years, but only 2% women. Conclusions Obesity/central should prioritized target programs. factors, vulnerability, not ignored addressed adequate guidance create equity.

Язык: Английский

Targeted nanozyme-enabled treatment of cardiovascular diseases DOI Creative Commons
Lin Liu,

Jie Lv,

Xiuxiu Wang

и другие.

Acta Materia Medica, Год журнала: 2025, Номер 4(1)

Опубликована: Янв. 1, 2025

Cardiovascular diseases (CVDs) pose a significant threat to human health due the high mortality and morbidity rates. Traditional drugs often have limited efficacy inherent constraints, such as low bioavailability notable side effects. As highly regarded therapeutic strategy, nanotechnology offers new perspectives means for treating CVDs. Nanozyme-based targeted specifically address biological processes in areas affected by CVDs, thereby achieving precise treatment. Compared traditional drugs, nanozymes offer advantages, efficiency, specificity, controllability, fewer effects, showing great This paper first explores design strategies mechanisms of nanozyme-based therapy, then introduces its application key ischemic stroke, myocardial infarction, coronary heart disease. Finally, discusses challenges introducing into clinical applications future development prospects treatment

Язык: Английский

Процитировано

1
Weighing in on the Heavy Psychological Tolls of Obesity DOI Creative Commons
Carl J. Lavie, Deepika Laddu, Ross Arena

и другие.

JACC Advances, Год журнала: 2024, Номер 3(8), С. 101114 - 101114

Опубликована: Июль 23, 2024

Язык: Английский

Процитировано

4
Tracking and Transition Probability of Blood Pressure From Childhood to Midadulthood DOI
Yaxing Meng, James E. Sharman,

Fiia Iiskala

и другие.

JAMA Pediatrics, Год журнала: 2024, Номер 179(1), С. 34 - 34

Опубликована: Ноя. 4, 2024

Despite its relevance for pediatric blood pressure (BP) screening, the long-term predictive utility and natural progression of BP classification remain understudied.

Язык: Английский

Процитировано

4
Association of social isolation and loneliness with incident cardiovascular diseases: results from a nationally prospective cohorts in China DOI

Jingru Zha,

Mingzhuang Chen

Social Psychiatry and Psychiatric Epidemiology, Год журнала: 2025, Номер unknown

Опубликована: Апрель 16, 2025

Язык: Английский

Процитировано

0
Intervention in School-Aged Children to Prevent Progression of Obesity and Cardiometabolic Disease DOI
Carl J. Lavie, Ian J. Neeland, Francisco B. Ortega

и другие.

Journal of the American College of Cardiology, Год журнала: 2024, Номер 84(6), С. 509 - 511

Опубликована: Июль 29, 2024

Язык: Английский

Процитировано

3
Metabolomics in Cardiovascular Diseases DOI
Shan Lu, Zhen Huang, Baiwei Liu

и другие.

International Journal of Drug Discovery and Pharmacology, Год журнала: 2024, Номер unknown, С. 100019 - 100019

Опубликована: Окт. 25, 2024

Review Metabolomics in Cardiovascular Diseases Shan Lu 1,†, Zisheng Huang 2,†, Baitao Liu 3, and Yan Zhang 1,* 1 Institute of Sciences Key Laboratory Molecular Sciences, School Basic Medical Ministry Education, Peking University Health Science Center, Beijing 100871, China 2 University, 3 Aerospace Clinical Medicine, † These authors contributed equally to this work. * Correspondence: [email protected] Received: 10 July 2023; Revised: 25 September 2024; Accepted: 26 Published: October 2024 Abstract: diseases (CVDs) are the leading cause death worldwide, disorders cardiac energy metabolism main contributors many cardiovascular pathologies. is a science that examines types amounts metabolites patterns change biological systems after stimulation or perturbation. Metabolites widely distributed body have universal regulatory effects on wide range physiological activities. Metabolism at end regulation life activities, so metabolomics closer phenotypes than genomics transcriptom-ics, can reflect state more accurately. Metabolomics, cross-cutting dis-cipline emerging post-genomics era, has rapidly penetrated into fields medicine, im-proves understanding complex generates new discoveries hypotheses. Therefore, helps detect metabolic changes course CVDs, search for biomarkers, further study pathogenesis CVDs. In review, we intend comprehensively summarize principles, classification applications CVDs metabolomics.

Язык: Английский

Процитировано

1
Pristimerin protects against pathological cardiac hypertrophy through improvement of PPARα pathway DOI Open Access

Ye Lu,

Zhaoxiang Zeng,

Xianhao Bao

и другие.

Toxicology and Applied Pharmacology, Год журнала: 2023, Номер 473, С. 116572 - 116572

Опубликована: Июнь 2, 2023

Язык: Английский

Процитировано

2
Multifunctional hybrid poly(ester-urethane)urea/resveratrol electrospun nanofibers for potential vascularizing matrix DOI
Liang Chen, Yanan Wang, Renliang Zhao

и другие.

Soft Matter, Год журнала: 2024, Номер 21(1), С. 55 - 67

Опубликована: Ноя. 26, 2024

P/R-1.0 nanofiber with excellent antioxidant, blood and cell compatibility fibricated via electrospinning for a potential vascularizing matrix.

Язык: Английский

Процитировано

0
Aggregation of cardiovascular risk factors in a cohort of 40-year-olds participating in a population-based health screening program in Sweden DOI Creative Commons
Beata Borgström Bolmsjö, Emelie Stenman,

Anton Grundberg

и другие.

Archives of Public Health, Год журнала: 2024, Номер 82(1)

Опубликована: Ноя. 28, 2024

Abstract Background It is important to identify and evaluate cardiovascular risk factors at an early stage address them accordingly. Among the younger population, metabolic syndrome less common than in older ages. However, each separate factor still has additive effect on burden. Non-metabolic that occur population include family history, smoking, psychological distress socioeconomic vulnerability. In 2021 a voluntary health intervention program was introduced urban area Sweden where cohort of 40-year-olds invited for identification. The aim this study how tend aggregate individuals participating screening associate with non-metabolic factors. Methods This cross-sectional 1831 participants. Data from questionnaires baseline measurements were used calculate prevalence metabolic- (blood pressure, lipids, fasting plasma glucose, BMI, waist-hip ratio) (family history CVD, distress, vulnerability) CVD. SCORE2 calculated according algorithm provided by working group ESC (European Society Cardiology) Cardiovascular Risk Collaboration. Associations among estimated using logistic regression presented as odds ratios (ORs) 95% confidence intervals (CIs). Results More half had least one factor, more 1/3 considered be suffering distress. Furthermore, obesity or central demonstrated individual associations all study; smoking (1.49; 1.32–2.63), CVD (1.41; 1.14–1.73), vulnerability (1.60; 1.24–2.07), (1.40; 1.14–1.72). According 25% men moderate (2.5–7.5%) developing event within 5–10 years, but only 2% women. Conclusions Obesity/central should prioritized target programs. factors, vulnerability, not ignored addressed adequate guidance create equity.

Язык: Английский

Процитировано

0